BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Goel R, Hong JS, Findling RL, Ji NY. An update on pharmacotherapy of autism spectrum disorder in children and adolescents. International Review of Psychiatry 2018;30:78-95. [DOI: 10.1080/09540261.2018.1458706] [Cited by in Crossref: 56] [Cited by in F6Publishing: 33] [Article Influence: 14.0] [Reference Citation Analysis]
Number Citing Articles
1 Stewart Campbell A, Needham BD, Meyer CR, Tan J, Conrad M, Preston GM, Bolognani F, Rao SG, Heussler H, Griffith R, Guastella AJ, Janes AC, Frederick B, Donabedian DH, Mazmanian SK. Safety and target engagement of an oral small-molecule sequestrant in adolescents with autism spectrum disorder: an open-label phase 1b/2a trial. Nat Med. [DOI: 10.1038/s41591-022-01683-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Uzun AD, Sapmaz ŞY, Öztürk M, Kandemir H. Hypertension Induced by Aripiprazole Use in an Autistic Child Patient. Clin Psychopharmacol Neurosci 2019;17:556-8. [PMID: 31671496 DOI: 10.9758/cpn.2019.17.4.556] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
3 D'Alò GL, De Crescenzo F, Amato L, Cruciani F, Davoli M, Fulceri F, Minozzi S, Mitrova Z, Morgano GP, Nardocci F, Saulle R, Schünemann HJ, Scattoni ML; ISACA guideline working group. Acceptability, equity, and feasibility of using antipsychotics in children and adolescents with autism spectrum disorder: a systematic review. BMC Psychiatry 2020;20:561. [PMID: 33238921 DOI: 10.1186/s12888-020-02956-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Iles A. Autism Spectrum Disorders. Prim Care 2021;48:461-73. [PMID: 34311851 DOI: 10.1016/j.pop.2021.04.003] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Cruz-Martins N, Quispe C, Kırkın C, Şenol E, Zuluğ A, Özçelik B, Ademiluyi AO, Oyeniran OH, Semwal P, Kumar M, Sharopov F, López V, Les F, Bagiu IC, Butnariu M, Sharifi-Rad J, Alshehri MM, Cho WC. Paving Plant-Food-Derived Bioactives as Effective Therapeutic Agents in Autism Spectrum Disorder. Oxid Med Cell Longev 2021;2021:1131280. [PMID: 34471461 DOI: 10.1155/2021/1131280] [Reference Citation Analysis]
6 Kawase H, Ago Y, Naito M, Higuchi M, Hara Y, Hasebe S, Tsukada S, Kasai A, Nakazawa T, Mishina T, Kouji H, Takuma K, Hashimoto H. mS-11, a mimetic of the mSin3-binding helix in NRSF, ameliorates social interaction deficits in a prenatal valproic acid-induced autism mouse model. Pharmacology Biochemistry and Behavior 2019;176:1-5. [DOI: 10.1016/j.pbb.2018.11.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
7 de Diego-Otero Y, Salgado-Cacho JM. Early detection in autism spectrum disorders. Med Clin (Barc) 2019;152:307-9. [PMID: 30678884 DOI: 10.1016/j.medcli.2018.11.023] [Reference Citation Analysis]
8 Mandic-maravic V, Grujicic R, Milutinovic L, Munjiza-jovanovic A, Pejovic-milovancevic M. Dopamine in Autism Spectrum Disorders—Focus on D2/D3 Partial Agonists and Their Possible Use in Treatment. Front Psychiatry 2022;12:787097. [DOI: 10.3389/fpsyt.2021.787097] [Reference Citation Analysis]
9 Shuai B, Jin H, Lin Y, Duan R, Zhao N, Li Z, Mao J, Luo Y, Shi M. Safety and efficacy of complementary and alternative medicine in the treatment of autism spectrum disorder: A protocol for systematic review and meta-analysis. Medicine (Baltimore) 2020;99:e23128. [PMID: 33157993 DOI: 10.1097/MD.0000000000023128] [Reference Citation Analysis]
10 D'Alò GL, De Crescenzo F, Minozzi S, Morgano GP, Mitrova Z, Scattoni ML, Amato L, Davoli M, Schünemann HJ; ISACA guideline working group. Equity, acceptability and feasibility of using polyunsaturated fatty acids in children and adolescents with autism spectrum disorder: a rapid systematic review. Health Qual Life Outcomes 2020;18:101. [PMID: 32299432 DOI: 10.1186/s12955-020-01354-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
11 Limandri BJ. Clinical Use of Dopamine Modulators as Third-Generation Antipsychotic Agents. J Psychosoc Nurs Ment Health Serv 2019;57:7-11. [PMID: 30703220 DOI: 10.3928/02793695-20190116-02] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
12 Fuentes J, Hervás A, Howlin P; (ESCAP ASD Working Party). ESCAP practice guidance for autism: a summary of evidence-based recommendations for diagnosis and treatment. Eur Child Adolesc Psychiatry 2021;30:961-84. [PMID: 32666205 DOI: 10.1007/s00787-020-01587-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
13 Aran A, Harel M, Cassuto H, Polyansky L, Schnapp A, Wattad N, Shmueli D, Golan D, Castellanos FX. Cannabinoid treatment for autism: a proof-of-concept randomized trial. Mol Autism 2021;12:6. [PMID: 33536055 DOI: 10.1186/s13229-021-00420-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
14 Yamasue H, Aran A, Berry-Kravis E. Emerging pharmacological therapies in fragile X syndrome and autism. Curr Opin Neurol 2019;32:635-40. [PMID: 31045620 DOI: 10.1097/WCO.0000000000000703] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 5.5] [Reference Citation Analysis]
15 Scarante FF, Ribeiro MA, Almeida-Santos AF, Guimarães FS, Campos AC. Glial Cells and Their Contribution to the Mechanisms of Action of Cannabidiol in Neuropsychiatric Disorders. Front Pharmacol 2020;11:618065. [PMID: 33613284 DOI: 10.3389/fphar.2020.618065] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
16 Lin TC, Lo YC, Lin HC, Li SJ, Lin SH, Wu HF, Chu MC, Lee CW, Lin IC, Chang CW, Liu YC, Chen TC, Lin YJ, Ian Shih YY, Chen YY. MR imaging central thalamic deep brain stimulation restored autistic-like social deficits in the rat. Brain Stimul 2019;12:1410-20. [PMID: 31324604 DOI: 10.1016/j.brs.2019.07.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
17 Stevanovic D, Wentz E, Nasic S, Knez R. ASD with ADHD vs. ASD and ADHD alone: a study of the QbTest performance and single-dose methylphenidate responding in children and adolescents. BMC Psychiatry 2022;22:282. [PMID: 35448977 DOI: 10.1186/s12888-022-03878-3] [Reference Citation Analysis]
18 Brandenburg C, Soghomonian JJ, Zhang K, Sulkaj I, Randolph B, Kachadoorian M, Blatt GJ. Increased Dopamine Type 2 Gene Expression in the Dorsal Striatum in Individuals With Autism Spectrum Disorder Suggests Alterations in Indirect Pathway Signaling and Circuitry. Front Cell Neurosci 2020;14:577858. [PMID: 33240045 DOI: 10.3389/fncel.2020.577858] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Baribeau D, Anagnostou E. Novel treatments for autism spectrum disorder based on genomics and systems biology. Pharmacol Ther 2021;:107939. [PMID: 34174273 DOI: 10.1016/j.pharmthera.2021.107939] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 McConkey R, Samadi SA, Mahmoodizadeh A, Taggart L. The Use of Psychotropic Medication in Iranian Children with Developmental Disabilities. Int J Environ Res Public Health 2021;18:4120. [PMID: 33924699 DOI: 10.3390/ijerph18084120] [Reference Citation Analysis]
21 Lovelace TS, Comis MP, Tabb JM, Oshokoya OE. Missing from the Narrative: A Seven-Decade Scoping Review of the Inclusion of Black Autistic Women and Girls in Autism Research. Behav Analysis Practice. [DOI: 10.1007/s40617-021-00654-9] [Reference Citation Analysis]
22 Yu Y, Chaulagain A, Pedersen SA, Lydersen S, Leventhal BL, Szatmari P, Aleksic B, Ozaki N, Skokauskas N. Pharmacotherapy of restricted/repetitive behavior in autism spectrum disorder:a systematic review and meta-analysis. BMC Psychiatry 2020;20:121. [PMID: 32164636 DOI: 10.1186/s12888-020-2477-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
23 Dhulkifle H, Agouni A, Zeidan A, Al-Kuwari MS, Parray A, Tolefat M, Korashy HM. Influence of the Aryl Hydrocarbon Receptor Activating Environmental Pollutants on Autism Spectrum Disorder. Int J Mol Sci 2021;22:9258. [PMID: 34502168 DOI: 10.3390/ijms22179258] [Reference Citation Analysis]
24 Ponton JA, Smyth K, Soumbasis E, Llanos SA, Lewis M, Meerholz WA, Tanguay RL. A pediatric patient with autism spectrum disorder and epilepsy using cannabinoid extracts as complementary therapy: a case report. J Med Case Rep 2020;14:162. [PMID: 32958062 DOI: 10.1186/s13256-020-02478-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
25 Ballester P, Espadas C, Londoño AC, Almenara S, Aguilar V, Belda C, Pérez E, Muriel J, Peiró AM. The challenge of detecting adverse events in adults with autism spectrum disorder who have intellectual disability. Autism Res 2021. [PMID: 34652075 DOI: 10.1002/aur.2624] [Reference Citation Analysis]
26 Kumar N, Zarate YA. Managing Sleep and Behavioral Problems in a Preschooler with SATB2-Associated Syndrome. Case Rep Genet 2020;2020:8868458. [PMID: 32765914 DOI: 10.1155/2020/8868458] [Reference Citation Analysis]
27 Hongkaew Y, Gaedigk A, Wilffert B, Gaedigk R, Kittitharaphan W, Ngamsamut N, Limsila P, Puangpetch A, Sukprasong R, Sukasem C. Pharmacogenomics Factors Influencing the Effect of Risperidone on Prolactin Levels in Thai Pediatric Patients With Autism Spectrum Disorder. Front Pharmacol 2021;12:743494. [PMID: 34690776 DOI: 10.3389/fphar.2021.743494] [Reference Citation Analysis]
28 Anderson CL, Evans V, Gorham L, Liu Z, Johnson CR, Carney PR. Seizure frequency, quality of life, behavior, cognition, and sleep in pediatric patients enrolled in a prospective, open-label clinical study with cannabidiol. Epilepsy Behav 2021;124:108325. [PMID: 34560358 DOI: 10.1016/j.yebeh.2021.108325] [Reference Citation Analysis]
29 Dawson G. Assessment of outcomes in autism clinical trials over the course of development. Eur Neuropsychopharmacol 2021;48:40-1. [PMID: 33731267 DOI: 10.1016/j.euroneuro.2021.02.018] [Reference Citation Analysis]
30 Bird F, Harper JM, Luiselli JK, Shlesinger A, Gold J. Psychotropic Medication Monitoring in a Human Services Organization for Children with Autism Spectrum Disorder: Description and Evaluation of Interdisciplinary Team Review. Behav Analysis Practice. [DOI: 10.1007/s40617-022-00699-4] [Reference Citation Analysis]
31 Higashida H, Munesue T, Kosaka H, Yamasue H, Yokoyama S, Kikuchi M. Social Interaction Improved by Oxytocin in the Subclass of Autism with Comorbid Intellectual Disabilities. Diseases 2019;7:E24. [PMID: 30813294 DOI: 10.3390/diseases7010024] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 5.7] [Reference Citation Analysis]
32 DelaCuesta-Barrutia J, Peñagarikano O, Erdozain AM. G Protein-Coupled Receptor Heteromers as Putative Pharmacotherapeutic Targets in Autism. Front Cell Neurosci 2020;14:588662. [PMID: 33192330 DOI: 10.3389/fncel.2020.588662] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
33 Pandina G, Ring RH, Bangerter A, Ness S. Current Approaches to the Pharmacologic Treatment of Core Symptoms Across the Lifespan of Autism Spectrum Disorder. Psychiatr Clin North Am 2020;43:629-45. [PMID: 33126999 DOI: 10.1016/j.psc.2020.08.003] [Reference Citation Analysis]
34 Marchezan J. Editorial: Autism Spectrum Disorder and Autoimmune Diseases: A Pathway in Common? J Am Acad Child Adolesc Psychiatry 2019;58:481-3. [PMID: 30902666 DOI: 10.1016/j.jaac.2019.03.014] [Reference Citation Analysis]
35 Searles Quick VB, Wang B, State MW. Leveraging large genomic datasets to illuminate the pathobiology of autism spectrum disorders. Neuropsychopharmacology 2021;46:55-69. [PMID: 32668441 DOI: 10.1038/s41386-020-0768-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
36 Pandina G, Ring RH, Bangerter A, Ness S. Current Approaches to the Pharmacologic Treatment of Core Symptoms Across the Lifespan of Autism Spectrum Disorder. Child Adolesc Psychiatr Clin N Am 2020;29:301-17. [PMID: 32169264 DOI: 10.1016/j.chc.2019.12.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Debi Ann A, Udayakumar N, Senta C, Rajanandh MG. Pyridoxine and Magnesium Administration-Induced Hyperactivity in Two Children With Autism Spectrum Disorder: Case Reports From a Clinical Trial. Clin Ther 2020;42:e250-8. [PMID: 33036783 DOI: 10.1016/j.clinthera.2020.09.010] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
38 Ann Abraham D, Narasimhan U, Christy S, Muhasaparur Ganesan R. Effect of L-Carnosine as adjunctive therapy in the management of children with autism spectrum disorder: a randomized controlled study. Amino Acids 2020;52:1521-8. [PMID: 33170378 DOI: 10.1007/s00726-020-02909-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
39 Joon P, Kumar A, Parle M. What is autism? Pharmacol Rep 2021;73:1255-64. [PMID: 33694100 DOI: 10.1007/s43440-021-00244-0] [Reference Citation Analysis]
40 Masri AT, Khatib F, Al Qudah A, Nafi O, Almomani M, Bashtawi M, Alomari F, Qutifan S, Qutifan A. Parental use of conventional and complementary therapy for autism in Jordan. Complement Ther Med 2020;48:102275. [PMID: 31987222 DOI: 10.1016/j.ctim.2019.102275] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
41 Alymov AA, Kapitsa IG, Voronina TA. Neurochemical Mechanisms of Pathogenesis and Pharmacological Correction of Autism Spectrum Disorders: Current Concepts and Prospects. Neurochem J 2021;15:129-38. [DOI: 10.1134/s1819712421020033] [Reference Citation Analysis]
42 Hong JS, Singh V, Kalb L. Attention Deficit Hyperactivity Disorder Symptoms in Young Children with Autism Spectrum Disorder. Autism Res 2021;14:182-92. [PMID: 33073542 DOI: 10.1002/aur.2414] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
43 Shaltout E, Al-Dewik N, Samara M, Morsi H, Khattab A. Psychological Comorbidities in Autism Spectrum Disorder. Adv Neurobiol 2020;24:163-91. [PMID: 32006360 DOI: 10.1007/978-3-030-30402-7_6] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
44 Pistollato F, Forbes-Hernández TY, Calderón Iglesias R, Ruiz R, Elexpuru Zabaleta M, Cianciosi D, Giampieri F, Battino M. Pharmacological, non-pharmacological and stem cell therapies for the management of autism spectrum disorders: A focus on human studies. Pharmacol Res 2020;152:104579. [PMID: 31790820 DOI: 10.1016/j.phrs.2019.104579] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
45 Huang Y, Huang X, Ebstein RP, Yu R. Intranasal oxytocin in the treatment of autism spectrum disorders: A multilevel meta-analysis. Neurosci Biobehav Rev 2021;122:18-27. [PMID: 33400920 DOI: 10.1016/j.neubiorev.2020.12.028] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]